Page 37 - Amgen News Today

Roche announces that its Tina-quant lipoprotein Lp RxDx test has been designated a breakthrough device by the U.S. FDA to identify patients likely to benefit from an innovative Lp-lowering therapy...

Swiss drug major Roche Holding AG (RHHBY) announced Wedensday that the Tina-quant lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.

/PRNewswire/ -- DelveInsights Infection Prevention and Control Market Insights report provides the current and forecast market analysis, individual leading...

The surge in the infection prevention and control demand market is due to factors such as the rising occurrence of chronic diseases, escalating rates of surgical procedures necessitating stringent

At Amgen, artificial intelligence is more than a technological advancement-its a pivotal force transforming the future of biotechnology. Were living through a hinge moment, merging tech and...

Judges ruled in favor of drug manufacturers ability to limit sales and distribution of discounted drugs in the governments 340B drug pricing program.

Jeff Mills. (Madrona Photo) Seattle-based venture capital firm Madrona is boosting its Silicon Valley footprint with the addition of Jeff Mills as partner

After the pandemic shined a spotlight on public health, it remains an in-demand field.

SAN DIEGO — A fragment antibody against thymic stromal lymphopoietin was safe and effective in reducing airway inflammation among patients with asthma, according to a presentation at the American Thoracic Society International Conference.“Thymic stromal lymphopoietin (TSLP) is involved in chronic inflammatory disorders, including asthma and COPD,” Maria Belvisi, PhD, senior vice

SAN DIEGO — Few patients are evaluated based on all seven endpoints of guidelines indicating complete asthma remission, according to a poster presented at the American Thoracic Society International Meeting. Standardized protocols that include all these domains are needed for accurate assessment of asthma remission, Thomas C. Corbridge, MD, FCCP, U.S. senior medical lead, respiratory